Semaglutide for Weight Loss — What Your Doctor Isn’t Telling You | Side Effects & Risks

Medically reviewed by Dr. Dan Xu, M.D., CCFP — CPSO Licensed Physician and Founder & Medical Director of ID Cosmetic Clinic, Markham. Last updated June 2026.

Few medications have generated as much noise — and as much misinformation — as semaglutide. Known by brand names like Ozempic and Wegovy, this GLP-1 receptor agonist has reshaped how medicine approaches obesity and weight management. With that popularity has come a flood of online claims: that it “melts your face,” that the weight always comes roaring back, that it damages your heart, that it causes cancer. Every week in our Markham clinic, patients arrive confused by these stories before they have even started. So let’s do what the headlines rarely do — sort the documented side effects from the exaggerated and the simply wrong, using what the clinical evidence actually shows.

Semaglutide side effects: myths vs facts

What semaglutide actually does — in one paragraph

Semaglutide mimics GLP-1, a gut hormone your body releases after eating. It slows how fast your stomach empties and acts on appetite centres in the brain to increase fullness and reduce hunger. That is the mechanism behind the weight loss — and, importantly, it is also the source of most of its real side effects. Understanding that one fact makes the rest of this article much clearer: many “side effects” are simply the flip side of how the medication works. Semaglutide is a prescription medication; in Canada it must be prescribed and supervised by a physician.

The side effects that are real

These are well-documented in clinical trials and real-world use. If you start semaglutide, these are the risks worth understanding and planning for — not the scary headlines, but the genuine ones.

Digestive symptoms: common, but usually temporary

Nausea, vomiting, diarrhea and constipation are the most common semaglutide side effects, reported by roughly 20–40% of people in trials. They cluster in the first weeks of starting — or after each dose increase — and tie directly to the drug slowing stomach emptying. The good news is that most people adapt within two to four weeks. The single most effective way to minimize them is a slow, standard dose-titration schedule (starting low and increasing gradually). If you feel nauseated early on, that is usually the expected adjustment process, not a sign the drug is wrong for you.

Marked appetite suppression: the mechanism is also a side effect

Reduced appetite is exactly how semaglutide produces weight loss — but pushed too far it has a downside. Some people eat too little, fall short on protein, and lose muscle along with fat. This is precisely why physician supervision matters: nutritional monitoring and dietary guidance are not optional extras to a GLP-1 plan, they are part of the treatment. Eating enough protein and maintaining strength are how you lose fat without losing the muscle you want to keep.

Injection-site reactions

As a subcutaneous injection, semaglutide can cause mild redness, itching or a small firm bump at the injection site. These are documented, generally minor, and short-lived. Properly rotating injection sites reduces them.

A small rise in resting heart rate

Studies show resting heart rate increases on average by about 1–4 beats per minute. For most healthy people this is not clinically meaningful. But if you have an arrhythmia or other underlying heart condition, this is a conversation to have with your physician before starting — which is one more reason these medications belong under medical supervision, not bought unsupervised online.

Myth 1: “Semaglutide causes ‘Ozempic face'”

The truth: “Ozempic face” — the gaunt, hollowed, slightly aged look some people develop — is not a toxic effect of the drug on your skin or facial tissue. It is the result of rapid weight loss. When you lose fat quickly across the whole body, the fat pads that give the cheeks and temples their youthful fullness shrink too, and the face can look deflated. This is not unique to Ozempic or Wegovy: any fast, large weight reduction — surgical, dietary, or otherwise — can do the same thing. The faster and larger the loss, the more visible the change. Moderating the pace of weight loss, keeping protein intake high, and adding strength training all help preserve facial structure. And not everyone who uses semaglutide develops a noticeable “Ozempic face” at all.

Myth 2: “The moment you stop, the weight comes straight back”

The truth: There is a documented tendency to regain weight after stopping, and it would be dishonest to pretend otherwise. The reason is mechanistic: GLP-1 receptor agonists work by suppressing appetite, not by permanently rewiring your metabolism. Stop the drug and the appetite suppression fades — and if old eating habits return with it, weight tends to climb back. But “instant, inevitable rebound” is a misread. The deciding factor is whether sustainable eating and exercise habits were built during treatment. People who combine GLP-1 therapy with genuine lifestyle change hold their results far better than those who relied on the drug alone. The medication is a tool; the lasting result comes from the habits.

Myth 3: “Semaglutide damages your heart”

The truth: This is the opposite of what the evidence shows. The SUSTAIN-6 trial (2016) and the much larger SELECT trial (2023) both found that semaglutide reduced major adverse cardiovascular events in people with existing cardiovascular disease or high risk — a cardioprotective effect. On the strength of that evidence, the U.S. FDA approved semaglutide (as Wegovy) in 2023 specifically to reduce cardiovascular risk. The “it hurts your heart” claim is a serious misreading of a drug that the data actually support for heart protection. The small resting heart-rate rise noted above is a separate, generally minor finding — not evidence of cardiac harm.

Myth 4: “It causes thyroid cancer”

The truth: The thyroid-cancer concern originates from early rodent studies, where high-dose, long-term exposure produced a signal for medullary thyroid carcinoma (MTC) in rats and mice. In humans, however, large clinical studies with tens of thousands of participants and years of follow-up have not shown a meaningful increase in thyroid cancer. Rodents and humans differ importantly in how their thyroid cells respond to GLP-1, which is part of why the rat signal did not translate. That said — and this matters — current guidelines still list semaglutide as contraindicated for people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 (MEN2). If that describes you, you must tell your physician up front.

Myth 5: “It causes pancreatitis”

The truth: Early epidemiological studies raised a question about whether GLP-1 medications might be linked to pancreatitis. But the more rigorous, large-scale cardiovascular outcome trials that followed (such as LEADER and SUSTAIN-6) did not find a significant association. The concern that remains is targeted, not blanket: people with a history of acute pancreatitis should be cautious, and the decision to use semaglutide should be made after a physician’s assessment — not ruled out for everyone based on a signal the bigger studies did not confirm.

Myth 6: “Nausea means the drug is wrong for you”

The truth: Early nausea is one of the most predictable and well-understood parts of starting semaglutide — it is the stomach adjusting to slower emptying, and it usually settles within two to four weeks. The standard solution is not to abandon treatment but to titrate slowly: begin at a low dose and increase gradually, giving your body time to adapt. Eating smaller, lower-fat meals during the start-up phase helps too. Persistent or severe symptoms should always be reviewed with your physician, but mild early nausea is an expected step, not a verdict.

Who should be cautious with semaglutide?

Semaglutide is not right for everyone, and honest screening is the whole point of starting under medical supervision. You should not use it, or should proceed only after careful physician assessment, if you have a personal or family history of medullary thyroid carcinoma or MEN2; a history of pancreatitis; certain serious gastrointestinal conditions (such as severe gastroparesis); significant underlying heart rhythm disorders; or if you are pregnant, breastfeeding or trying to conceive. People who eat very little at baseline or are at risk of losing muscle need particularly close nutritional monitoring. A proper consultation reviews your full history, screens for contraindications, and checks baseline metabolic markers before any prescription is written. This article is general information, not medical advice — your candidacy can only be decided in a personal medical assessment.

How to reduce side effects: why supervision matters

Knowing the truth about side effects is not the same as being able to self-prescribe. Three things make GLP-1 treatment safer and more effective, and all three are hard to do alone:

• Dose titration. The standard approach starts at a low dose (commonly 0.25 mg/week) and increases roughly every four weeks toward an individualized target. This gradual climb is the core strategy for minimizing digestive side effects — chasing a high dose quickly is how people make themselves miserable.
• Dietary adjustment. During the adjustment phase: favour lower-fat, less spicy meals; eat small and often; don’t inject on a completely empty stomach; keep protein intake adequate (at least ~1.2 g per kg of body weight) to protect muscle; and stay well hydrated, since reduced appetite can quietly lead to dehydration.
• Regular follow-up and monitoring. GLP-1 therapy is not “one injection and wait.” Proper care includes periodic checks of weight, body composition (muscle-to-fat ratio), metabolic markers (blood glucose, lipids, liver function) and quality of life, with the plan adjusted to the results. This monitoring is the real difference between supervised medical treatment and unsupervised use of product bought online.

The real takeaway

Semaglutide is a genuinely powerful, well-studied medication — and like any such medication, it has real side effects that deserve respect, not panic. The honest summary is this: the documented effects (digestive upset, appetite suppression, a small heart-rate rise) are mostly manageable with slow titration and supervision, while the scariest viral claims (face-melting toxicity, inevitable rebound, heart damage, cancer) are either misread mechanisms or rodent signals that human evidence has not confirmed. Used as a supervised tool alongside sustainable habits — not as an unsupervised shortcut — weight loss with semaglutide can be safe and durable rather than an anxious gamble.

Frequently asked questions

What are the most common semaglutide side effects?

Digestive symptoms — nausea, vomiting, diarrhea and constipation — are the most common, affecting roughly 20–40% of people. They typically appear when starting or increasing the dose and usually ease within two to four weeks as the body adapts.

How long does semaglutide nausea last?

For most people, early nausea settles within about two to four weeks. A slow dose-titration schedule and smaller, lower-fat meals during the start-up phase reduce it. Severe or persistent nausea should be reviewed with your physician.

Is “Ozempic face” caused by the drug?

No. “Ozempic face” — facial hollowing — is caused by rapid weight loss, not drug toxicity. Any fast, large weight drop can do the same. Slowing the pace of loss, keeping protein high and adding strength training help preserve facial fullness.

Does the weight come back after you stop semaglutide?

There is a tendency to regain weight after stopping, because the drug suppresses appetite rather than permanently changing metabolism. But it is not instant or inevitable — people who build sustainable diet and exercise habits during treatment maintain their results much better.

Is semaglutide bad for your heart?

No. Large trials (SUSTAIN-6 and SELECT) showed semaglutide reduced major cardiovascular events, and the FDA approved it to lower cardiovascular risk. There is a small average rise in resting heart rate, which is generally not clinically significant in healthy people.

Does semaglutide cause thyroid cancer?

Human studies have not shown an increase in thyroid cancer; the concern came from high-dose rodent studies. However, it remains contraindicated for people with a personal or family history of medullary thyroid carcinoma or MEN2, who should tell their physician before starting.

Can semaglutide cause pancreatitis?

Early studies raised the question, but large cardiovascular outcome trials did not confirm a significant link. Caution applies mainly to people with a history of acute pancreatitis, who should only use it after a physician’s assessment.

Who should not take semaglutide?

People with a history of medullary thyroid carcinoma or MEN2, prior pancreatitis, certain serious gastrointestinal or heart-rhythm conditions, and those who are pregnant or breastfeeding should avoid it or proceed only after careful physician assessment.

Why does semaglutide need physician supervision?

It is a prescription medication that requires screening for contraindications, careful dose titration to minimize side effects, nutritional guidance to protect muscle, and ongoing monitoring of weight, body composition and metabolic markers — none of which is safe to manage with unsupervised, online-bought product.

Related at ID Cosmetic Clinic

• Treatment: Physician-Supervised GLP-1 / Medical Weight Loss
• Treatment: Semaglutide Weight-Loss Program
• Condition: Weight Management
• Read next: “Ozempic Face”: Why Rapid Weight Loss Changes Your Face
• Guide: What to Expect From a Supervised GLP-1 Weight-Loss Program